Moffitt Presentations at ASH 2023

Note - all times are listed as PST

Friday, December 8, 2023

Time	Location	Type	Title	Author/Presenter
11:00 - 2:00pm	Room 6B (San Diego Convention Center	Satellite Symposia	Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?	Andrew T. Kuykendall, MD (chair)
1:30 - 2:00pm; 2:40 - 3:10pm; 4:35 - 5:00pm	Sections 122 and 124 (Petco Park)	ASH-a-Palooza Program	Blood Buddies: Adult Clinical Malignant Hematology	Alison R. Walker, MD, MPH, MBA (speaker)
1:30 - 2:00pm; 2:40 - 3:10pm; 4:35 - 5:00pm	Sections 122 and 124 (Petco Park)	ASH-a-Palooza Program	Blood Buddies: BMT Pediatric and Adult	Hany Elmariah, MD, MS (speaker)
2:05 - 2:45pm	Room 11 (San Diego Convention Center)	Symposia	Biomarkers of Biological Aging in Hematologic Malignancies	Martine Extermann, MD, PhD (session moderator), Rebecca S. Hesterberg, PhD (speaker)
2:45 - 3:20pm	Room 11 (San Diego Convention Center)	Symposia	Gauging Response of BiTes and CAR-T in Aging Adults	Ciara L. Freeman, PhD, MSc, FRCPC, MRCP (session moderator)
3:00 - 6:00pm	Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)	Satellite Symposia	Putting Your Stamp on the Next Generation of Care in CML: Improving Outcomes from Frontline to R/R Treatment Settings	Amanda Rodriguez, PA-C (speaker)
3:00 - 6:00pm	Room 6DE (San Diego Convention Center)	Satellite Symposia	Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome	Rami S. Komrokji, MD (speaker)
4:30 - 5:00pm	Left Field Concourse (Petco Park)	ASH-a-Palooza Program	Blood Drop: Diversity, Equity, and Inclusion	Alison R. Walker, MD, MPH, MBA (speaker)

Saturday, December 9, 2023

Time	Location	Type	Title	Author/Presenter
9:30am	Ballroom 20AB (San Diego Convention Center)	Oral	73 A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia	Andrew T. Kuykendall, MD
9:30 - 10:45am	Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)	Educational	What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?	Alison R. Walker, MD, MPH, MBA (session chair)
9:30 - 10:45am	Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)	Educational	Are We Personalizing MDS Therapy in 2023?	David A. Sallman, MD (session chair)
9:30 - 11:00am	Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)	Session Moderator	Session 802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders	Fabiana Perna, MD, PhD
10:30am	Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)	Oral	137 Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera	Andrew T. Kuykendall, MD
11:15am - 12:15pm	Sapphire Ballroom ABCD (Hilton San Diego Bayfront)	Educational	Career Development Lunch	Leidy Lismeris Isenalumhe, MD, MS (session chair), Kendra Sweet, MD (speaker), Brandon Blue, MD (speaker)
2:00 - 3:15pm	Room 6DE (San Diego Convention Center)	Scientific Symposia	Alternative Immune Effector Cells	Fabiana Perna, MD, PhD
2:00 - 3:30pm	Room 6CF (San Diego Convention Center)	Session Moderator	Session 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors	Michael D. Jain, MD, PhD (session moderator)
2:15pm	Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)	Oral	194 Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study	Rami S. Komrokji, MD
4:00 - 5:15pm	Room 6DE (San Diego Convention Center)	Educational	Hematologic Toxicity of Immunotherapies	Frederick L. Locke, MD (session chair)
5:15pm	Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)	Oral	390 Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations	Teresa Caprice, PA-C
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1931 Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines	Ciara L. Freeman, PhD, MSc, FRCPC, MRCP
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1750 A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy	Aditi Saha, MBBS
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1776 A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma	Aditi Saha, MBBS
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1867 Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) Is Associated with Better Overall Survival	Rami S. Komrokji, MD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2130 Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma	Khushali Jhaveri, MD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1911 Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study	Mohammad Ammad Ud Din, MBBS
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2343 Safety and Financial Analysis of Outpatient Hypercvad Arm a Administration for Acute Lymphoblastic Leukemia	Yujiao Sun, PharmD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2280 Ex Vivo Mathematical Myeloma Advisor (EMMA) a Clinical, Molecular, and Phenotypic Platform to Tailor Personalized Therapeutic Strategies for Multiple Myeloma	Rafael Renatino-Canevarolo, PhD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2177 JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results	Joseph Pidala, MD, PhD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2414 Geographic and Racial Disparities in Chimeric Antigen Receptorâ€“T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma	Moazzam Shahzad, MD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1820 Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study	Rami S. Komrokji, MD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2440 Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database	Rami S. Komrokji, MD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	2095 ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas	Frederick L. Locke, MD
5:30 - 7:30pm	Halls G-H (San Diego Convention Center)	Poster	1662 Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial	Sameh Gaballa, MD

Sunday, December 10, 2023

Time	Location	Type	Title	Author/Presenter
9:30 - 11:00am	Hall A (San Diego Convention Center)	Special Interest Session	Special Scientific Session on Race and Science: Bench to Bedside to the Community	Alison R. Walker, MD, MPH, MBA (session co-chair)
12:15 - 1:15pm	Room 33 (San Diego Convention Center)	Educational	Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia	Timothy Kubal, MD, MBA (speaker)
12:30pm	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)	Oral	543 Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma	Doris Hansen, MD
4:30 - 6:00pm	Harbor Ballroom (Manchester Grand Hyatt San Diego)	Session Moderator	Session 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States	Kenneth Shain, PhD, MD
4:30 - 6:00pm	Room 24 (San Diego Convention Center)	Special Interest Session	Blood and Beyond	Alison R. Walker, MD, MPH, MBA (session co-chair)
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3500 CAR-T Phenotype and Efficacy Is Impaired By Lymphoma-Associated CD39+ T Cells	Michael D. Jain, MD, PhD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3506 CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma	Jerald Noble, PhD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3351 Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy	Ariel F. Grajales-Cruz, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3301 Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma	Praneeth Reddy Sudalagunta, PhD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3304 Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease	Ciara L. Freeman, PhD, MSc, FRCPC, MRCP
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4678 Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies	Ciara L. Freeman, PhD, MSc, FRCPC, MRCP
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	5081 Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience	Lauren C. Peres, PhD, MPH
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3138 B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)	Ning Dong, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	2899 Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance	Mary Burke, PharmD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	2830 Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia	Rawan Faramand, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3078 A Retrospective Study of Extracorporeal Photopheresis (ECP) in Treatment of Cutaneous T-Cell Lymphoma (CTCL) Evaluating Global, Skin and Blood Responses	Ning Dong, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3614 Outcomes of Allogenic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older	Moazzam Shahzad, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	2661 Nationwide Analysis of Characteristics and Outcomes of Patients with Heparin Induced Thrombocytopenia Admitted for Treatment of COVID-19	Muhammad Ammad Ud Din, MBBS
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	2916 Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study	Jeffrey Lancet, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	3523 Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation	Moazzam Shahzad, MD

Monday, December 11, 2023

Time	Location	Type	Title	Author/Presenter
12:15 - 1:15pm	Room 33 (San Diego Convention Center)	Educational	Trainee Didactic Session: What to Ask For in an Interview	Alison R. Walker, MD, MPH, MBA (speaker)
2:45 - 4:00 pm	Ballroom 20AB (San Diego Convention Center)	Educational	What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together	Asmita Mishra, MD, MBA
2:45 - 4:00 pm	Room 7 (San Diego Convention Center)	Educational	Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL	Zhuoer Xie, MD, MS
2:45 - 4:00 pm	Room 7 (San Diego Convention Center)	Spotlight Session	CCUS is Increasingly Significant in Clinical Practice	Zhuoer Xie, MD, MS (speaker)
4:00pm	Room 6A (San Diego Convention Center)	Oral	894 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)	Julio C. Chavez, MD
4:45pm	Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)	Oral	1004 A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel	Doris K. Hansen, MD
5:15pm	Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)	Oral	994 MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms	Nicole D. Vincelette, PhD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4900 Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant	Hany Elmariah, MD, MS
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4879 Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3	Rachid Baz, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4884 Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma	Filip Ionescu, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4611 Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias	Zhuoer Xie, MD, MS
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4620 Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)	David Sallman, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4846 Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report	Nelli Bejanyan, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	5083 Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial	Doris K. Hansen, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	5136 Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)	Bijal D. Shah, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	5137 Real-World Patterns of Care and Financial Burden of Patients with Follicular Lymphoma in the United States	Bijal D. Shah, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	5155 Real-World Switching Pattern, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States	Bijal D. Shah, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	5166 Risks and Outcomes of Tumor Lysis Syndrome in Patients Admitted with Diffuse Large B Cell Lymphoma; A Nationwide Analysis	Muhammad Farooq, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4804 Chimeric Antigen Receptor T Cells Targeting LILRB4, an Immunoreceptor Mediating T-Cell Suppression, Are Potently Effective in Multiple Myeloma	Francesco Di Meo
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4530 SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms	Garima Pandey, PhD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4591 Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study	Rami S. Komrokjil, MD
6:00 - 8:00pm	Halls G-H (San Diego Convention Center)	Poster	4235 Clinical Outcomes and Cardiovascular Adverse Events of Patients with Acute Myeloid Leukemia Treated with Venetoclax Plus a Hypomethylating Agent or Low-Dose Cytarabine in the Veterans Health Administration: A National Retrospective Cohort Study	Gabriel Roman Souza, MD

Business of Biotech

Meet and collaborate with the innovators of our age. This conference historically attracts over 400 biotech executives, entrepreneurs, venture capitalists, angel investors and researchers from across the U.S.

Conference Information, Registration

Moffitt Presentations at ASH 2023

Note - all times are listed as PST

Business of Biotech

Cambiar el idioma